The limited duration of humoral responses to vaccination is a key issue in the fight against infectious diseases, as antibody levels wane over time, leaving individuals vulnerable to reinfection.
Stanford researchers have developed a more sensitive and accurate pathogenic infection diagnosis method using intact genetically modified pathogens. Pathogen infection clinical diagnosis requires direct pathogen detection or the detection of pathogen specific antibodies.
Researchers at Stanford have developed a novel strategy to enhance vaccine efficacy using mRNA lipid nanoparticles (LNPs) encoding immunostimulatory cytokines.
Stanford scientists have identified tuberculosis (TB) epitopes preferentially recognized by T cells in patients who naturally resist or control TB infection. Targeting these epitopes for vaccine development could lead to effective vaccines for TB.
Stanford researchers have developed a nanoparticle adjuvant with spatiotemporal controlled release of TLR7 agonist for broad protection against influenza or SARS-CoV-2.
Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.
Stanford researchers have developed a multi-omics method for predicting the strength and durability of immune responses to vaccines shortly after vaccination. The COVID-19 pandemic was a grave demonstration of the threat pandemics pose to global public health.